Document Detail

Treatment of intracranial atherosclerotic disease with a balloon-expandable paclitaxel eluting stent: procedural safety, efficacy and mid-term patency.
Jump to Full Text
MedLine Citation:
PMID:  22252289     Owner:  NLM     Status:  MEDLINE    
PURPOSE: Procedural safety and high rates of in-stent recurrent stenotic lesions (ISR) remain a concern in the endovascular treatment of intracranial atherosclerotic disease (ICAD). In the present study technical feasibility, safety and efficacy of the paclitaxel eluting balloon-expandable coronary stent Coroflex(®) Please was assessed in the treatment of ICAD.
METHODS: A total of 95 patients (79 male; median age 68 years) with 106 intracranial atherosclerotic stenotic lesions underwent endovascular treatment using Coroflex(®) Please stents (B. Braun, Melsungen, Germany). Location and degree of target stenoses before and after treatment and at follow-up and adverse clinical sequelae of treatment were registered. Post-procedural medication included 100 mg acetylsalicylic acid (ASA) and 75 mg clopidogrel for 1 year. Angiographic follow-up was scheduled for 6, 12, 26 and 52 weeks after the treatment.
RESULTS: The lesion locations were as follows: internal carotid artery (ICA) petrous (n = 44, 42%), ICA cavernous (n = 43, 41%), ICA paraclinoid (n = 4, 4%), intradural vertebral artery (VA; n = 11, 10%) and basilar artery (BA; n = 4, 4%). Of the lesions seven could not be treated due to difficult anatomy and stent stiffness (7% technical failure rate). The combined post-interventional neurological morbidity and mortality rate, including stroke, intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH) and carotid cavernous fistula (CCF) was n = 4 (3.7%) within and n = 1 (0.9%) at and beyond 30 days, respectively. Angiographic and clinical follow-up examinations were carried out for 78 (78%) of the lesions (mean 16.1 months, maximum 48 months). Asymptomatic recurrent stenosis was seen in 3 out of 78 (3.8%) lesions and there was 1 case of late stent thrombosis (0.9%).
CONCLUSIONS: Treatment of ICAD using drug-eluting coronary stents is safe and effective but technical failure due to stent stiffness remains a problem. Application of the more flexible, newest generation thin-strut stents, however, shows promising results.
Z Vajda; M Aguilar; T Göhringer; D Horváth-Rizea; H Bäzner; H Henkes
Related Documents :
20364419 - Etiopathogenesis of neurogenic pulmonary edema.
21289129 - Current perspectives on management of congenital jugular vein aneurysms.
3766599 - Diffuse pulmonary injury following paint remover exposure.
17664539 - Medialisation thyroplasty for unilateral vocal fold paralysis associated with chronic p...
12206859 - Carbazochrome attenuates pulmonary dysfunction induced by a radiographic contrast mediu...
1389799 - Pulmonary edema during pregnancy.
9445349 - Apoptosis of medial smooth muscle cells in the development of saccular cerebral aneurys...
23555479 - Surgical treatment for aortic coarctation with chronic type b dissection: report of a c...
15129329 - Endovascular stenting for restenosis of the intracranial vertebrobasilar artery after b...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2012-01-18
Journal Detail:
Title:  Clinical neuroradiology     Volume:  22     ISSN:  1869-1447     ISO Abbreviation:  Clin Neuroradiol     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-09-03     Completed Date:  2013-01-31     Revised Date:  2013-06-26    
Medline Journal Info:
Nlm Unique ID:  101526693     Medline TA:  Clin Neuroradiol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  227-33     Citation Subset:  IM    
Klinik für Neuroradiologie, Neurozentrum, Klinikum Stuttgart, Kriegsbergstr. 60, 70174 Stuttgart, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Angioplasty, Balloon / instrumentation*
Drug-Eluting Stents*
Intracranial Arteriosclerosis / radiography*,  surgery*
Middle Aged
Paclitaxel / administration & dosage*
Treatment Outcome
Vascular Patency
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Clin Neuroradiol
Journal ID (iso-abbrev): Clin Neuroradiol
ISSN: 1869-1439
ISSN: 1869-1447
Publisher: Springer-Verlag, Berlin/Heidelberg
Article Information
Download PDF
© The Author(s) 2011
Received Day: 2 Month: 8 Year: 2011
Accepted Day: 16 Month: 12 Year: 2011
Electronic publication date: Day: 18 Month: 1 Year: 2012
pmc-release publication date: Day: 18 Month: 1 Year: 2012
Print publication date: Month: 9 Year: 2012
Volume: 22 Issue: 3
First Page: 227 Last Page: 233
ID: 3432207
PubMed Id: 22252289
Publisher Id: 125
DOI: 10.1007/s00062-011-0125-y

Treatment of Intracranial Atherosclerotic Disease with a Balloon-Expandable Paclitaxel Eluting Stent : Procedural Safety, Efficacy and Mid-Term Patency
Z. Vajda1
M. Aguilar1
T. Göhringer1
D. Horváth-Rizea1
H. Bäzner3 Address:
H. Henkes12
1Klinik für Neuroradiologie, Neurozentrum, Klinikum Stuttgart, Kriegsbergstr. 60, 70174 Stuttgart, Germany
2Medizinische Fakultät der Universität Duisburg-Essen, Essen, Germany
3Klinik für Neurologie, Neurozentrum, Klinikum Stuttgart, Stuttgart, Germany


Intracranial atherosclerotic stenoses are responsible for at least 8–10% of ischemic strokes [1]. The warfarin-aspirin symptomatic intracranial disease study (WASID, [2]) and the extracranial-intracranial bypass study [3] demonstrated suboptimal results for the medical or unselected surgical management of these lesions. Early endovascular attempts with balloon dilatation alone did not gain widespread adoption due to issues of vessel dissection and early elastic recoiling [46] but these issues can be overcome by the application of stents. The options for stent treatment in intracranial stenotic lesions include primary stenting by implantation of a balloon-mounted bare metal [7] and drug-eluting stents (DES; [812]) designed originally for the coronary vasculature or dedicated for neurovascular application [13] or secondary implantation of a slightly oversized self-expanding stent following a moderately undersized balloon dilatation [14]. Despite continuously growing experience in patient selection, procedural feasibility, safety and the durability of revascularization, high rates (24–31%) of recurrent stenosis still remain the main drawback of intracranial stenting [15,16]. Achieving lower recurrence rates following intracranial stenting is therefore of major importance, although promising results of effective re-treatment of recurrent in-stent stenotic lesions have been shown recently by dilatation using a drug-eluting balloon [17,18].

The application of sirolimus or paclitaxel eluting balloon mounted coronary stents has already been shown to be a feasible, efficient and cost-effective treatment of intracranial stenotic lesions [812]. The experience is, however, still rather limited with a total of 82 published cases to the best of our knowledge, performed in several centers applying a variety of stents and treatment protocols.

This article presents data on the procedural safety, efficacy and mid-term patency rates from a retrospective series of stent treatment of 106 intracranial atherosclerotic stenotic lesions, performed in a single institution under a standardized periprocedural and postprocedural protocol and patient management, using the same type of drug-eluting stent.

Materials and Methods
Patient Selection

The present series comprised 95 consecutive patients who underwent elective endovascular treatment of 106 significant (³ 50%) intracranial atherosclerotic arterial stenoses in the period from March 2007 to August 2011 in a single institution by or under the supervision of the senior author, according to identical principles of the entire procedural management.

Endovascular treatment using the Coroflex® Please (B. Braun, Melsungen, Germany) stent was offered to patients with an intracranial stenotic lesion, if the lumen loss at the stenotic vessel segment was ³ 50% and this stenosis was either symptomatic, progressive or accompanied by other stenoses. Previous failure of medical treatment was not considered a compulsory criterion.

Stenotic lesions located on the intradural internal carotid artery (ICA), the intradural vertebral artery (VA) and the trunk of the basilar artery (BA) were included in the study.

Patients were selected for the treatment of stenosis with a DES on the basis of anatomical criteria. Arguments in favor for the use of a DES were straight proximal vessels without excessive atherosclerotic tortuosity, no major caliber differences of the target vessel proximal and distal to the stenotic segment and a distal vasculature allowing for a sufficiently distant insertion of the microguidewire. In addition to formal criteria, the anticipated ease or difficulty of the access to a given intracranial stenosis with a relatively rigid stent was also considered. The extradural or intradural location of the target stenosis per se was of no relevance for this decision-making.

All patients were explicitly advised about the off-label intracranial use of the drug-eluting coronary stent. (Comment: In German jurisdiction, off-label use of medical devices is exempt from prosecution, if the patient has a serious, e.g. potentially life-threatening disorder, there is no reasonable or only a less favorable therapeutic alternative, available scientific data justify the expectation that with this device a better if not successful outcome could be achieved and the patient or legal representative is informed about the off-label character as well as about the procedural risks and potential treatment alternatives.)

Treatment was considered indicated if the target stenosis was symptomatic or progressive during follow-up or if the affected vessel had no sufficient collaterals or if a stenosis of the contralateral vessel has been symptomatic. These circumstances are considered to carry an increased risk of subsequent cerebral ischemia.


The periprocedural management included a neurological examination by an independent neurologist prior to and after the endovascular treatment, brain magnetic resonance imaging/magnetic resonance angiography (MRI/MRA) and the administration of dual medical platelet anti-aggregation therapy. A loading dose of 500 mg acetylsalicylic acid (ASA) and 600 mg clopidogrel was given at least 1 day prior to treatment followed by 100 mg ASA and 75 mg clopidogrel daily for at least 1 year and 100 mg ASA daily thereafter. All endovascular procedures were carried out with the patient under general anesthesia via a 6 F or 8 F guiding catheter. During the procedure, standard medication included 5000 U heparin i.v., 500 mg ASA i.v. and 2 mg glycerine trinitrate intra-arterially (i.a.) for prevention of mechanically induced vasospasm. The target stenosis was visualized without other over-projecting vessels and with the least possible foreshortening. The normal vessel diameter adjacent to the stenosis and the diameter and length of the stenosis were determined using the calibrated measurement program of the Axiom Artis digital subtraction angiography (DSA) system (Siemens, Erlangen, Germany). Under a single road map the vessel distal to the stenosis was catheterized with a Silverspeed (ev3, Irvine, CA, USA) or Traxcess14 (Terumo, Somerset, NJ, USA) microguidewire. The diameter of the Coroflex® Please stent was selected to reach about 80% of the diameter of the normal vessel. The stents were implanted at nominal pressure (10 atm) with a manometer. After deflation and withdrawal of the balloon catheter a final DSA run was carried out to confirm the result and to exclude complications. During the first days after the procedure all possible efforts were undertaken to maintain the systolic blood pressure at £ 130 mmHg. Prior to discharge all patients underwent MRI as well as a clinical examination. Angiographic follow-up was scheduled for 6 and 12 weeks, 6 and 12 months and yearly thereafter. The follow-up angiography included DSA runs with projections and magnifications equivalent to those used for the original treatment. On these occasions patients were clinically examined and interviewed specifically for intermittent ischemic events.


A total of 95 patients (median age 68 years, age range 44–84 years, male-to-female ratio 79/16) with 106 intracranial atherosclerotic lesions were treated. The lesions were located as follows: ICA petrous (n = 44, 42%), ICA cavernous (n = 43, 41%), ICA paraclinoid (n = 4, 4%), intradural VA (n = 11, 10%) and BA (n = 4, 4%). The distribution of the lesions within the intradural and extradural segments was 19 (18%) and 87 (82%), respectively.

Of the 106 intracranial lesions 14 (13%) were asymptomatic, 65 (61%) were symptomatic with transient ischemic attacks (TIA), stroke or silent infarcts in the area of the affected vessel and 27 (25%) lesions were treated in the setting of multivessel disease. Multivessel disease was defined as stenotic lesion of the intracranial ICA or VA with occlusion, hypoplasia or high-grade stenosis of the corresponding contralateral vessel or segments of the circle of Willis, e.g. missing A1 segment of the contralateral anterior cerebral artery (ACA) or missing/hypoplastic P1 segment of the ipsilateral posterior cerebral artery (PCA).

The severity of the stenosis was 50–69% in 80 (75%) and 70–95% in 26 (25%) of the lesions. The average degree of target stenoses was determined as 64.9 ± 1% before and 16.4 ± 1% after the treatment. A summary of lesion characteristics is given in Table 1.

In seven lesions (7%) the Coroflex® Please stent could not be advanced into the stenotic segment due to an extremely elongated supra-aortic vascular anatomy, an elongated and calcified carotid siphon or due to the stiffness of the shaft tip or the stent itself. The treatment of these lesions was completed using either a more flexible bare metal coronary stent (Coroflex® Blue Ultra, B. Braun, Melsungen, Germany) or by undersized balloon dilatation followed by the implantation of a self-expanding nitinol stent (Enterprise, Codman, New Brunswick, NJ, USA).

Technical success, defined as less than 50% residual stenosis at the end of the procedure, was achieved in all of the cases where the Coroflex® Please stent could be implanted (n = 99, 100%; Fig. 1).

Of the procedures where the Coroflex® Please stent could be implanted, 94 (94.9%) were completed without any complication. A direct carotido-cavernous sinus fistula was encountered during the treatment of three stenotic lesions (2.8%) of the cavernous ICA (two of these lesions were symptomatic with TIAs) as major complication, requiring further endovascular treatment. No permanent neurological deficit resulted from these dissections. The fourth adverse event was a large hemodynamic infarction of the contralateral hemisphere following the treatment of a high-grade stenotic lesion of the right cavernous ICA and chronic occlusion of the left ICA. Due to extreme tortuosity of the supra-aortic vessels, direct access was established by direct puncture of the cervical right CCA. There were no signs of complication during the interventional procedure itself. At the end of the procedure the patient was transferred to the operating room (OR) and the introducer sheet was removed surgically. Following extubation the patient developed high grade hemiparesis on the right side [modified Rankin Scale (mRS) grade 4] with territorial infarcts without significant improvement during the 4-month follow-up period, resulting in a procedure related neurological morbidity beyond 30 days of 0.9%. There was one case (0.9%) of asymptomatic dissection of the stented segment without any clinical relevance. Vasospasm requiring treatment was not encountered. Thus the combined procedure-related neurological morbidity and mortality rate, including stroke, intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH) and carotid cavernous fistula (CCF) was 4/106 (3.8%) within 30 days and 1/106 (0.9%) at 30 days and beyond, respectively.

Angiographic and clinical follow-up examinations were obtained in 78 (78%) of the lesions. The average follow-up period was 16.1 months and the longest follow-up period was 48 months.

Recurrent stenosis, defined as an in-stent stenotic lesion of more than 50% lumen diameter reduction on the follow-up DSA series, was seen in 3 out of 78 (3.8%) lesions after 190, 224 and 233 days, respectively. All of these recurrent lesions were located in the intracranial ICA and were asymptomatic (Fig. 2). One case of late stent thrombosis (0.9%) occurred 3 months after the DES implantation in the cavernous segment of the left ICA in a 60-year-old male patient. The first DSA follow-up examination in this patient, 6 weeks after the stent implantation showed full patency of the stented segment without any sign of a recurrent lesion. The patient suffered from concomitant cardiac arrest with a poor clinical outcome.

Stent migration was not observed.


Atherosclerotic stenotic lesions of the intracranial arteries account for 8–10% of ischemic strokes [19]. The efficacy of medical and surgical treatment options for intracranial atherosclerotic disease (ICAD) is suboptimal: the WASID study showed that in patients on best medical care, symptomatic intracranial disease carried at least a 9–12% annual risk of major stroke or death [2], whereas the extracranial-intracranial bypass study demonstrated more frequent and earlier occurrence of both nonfatal and fatal stroke following the creation of an extracranial-intracranial (EC-IC) bypass, despite the impressive postoperative bypass patency rate of 96% [3]. The above mentioned issues sparked the interest in the endovascular treatment options of ICAD. The experience with balloon angioplasty alone without stent implantation is limited and results are rather unconvincing with weaknesses, such as elastic recoil and dissection [5,6]. The application of balloon-mounted or self-expandable bare metal stents is an established treatment option for ICAD, although procedural safety and recurrent lesions remain a concern [15]. The National Institute of Neurological Disorders and Stroke (NINDS) has recently stopped patient enrollment in the Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) study, which is the first prospective randomized multicenter trial with 50 participating centers in North America, evaluating whether intracranial angioplasty combined with stenting adds benefit to aggressive medical therapy alone for preventing stroke in patients with symptomatic intracranial arterial stenosis [20]. The reason for the premature halt was the high periprocedural complication rate with a 14% rate of stroke or death in patients treated with angioplasty and stenting within the first 30 days, compared with 5.8% of patients treated with medical therapy alone, whereas beyond 30 days, the rates of stroke in the territory of the stenotic artery were similar in the 2 groups [21].

High rates of in-stent restenotic (ISR) lesions are also problematic: case series of stent treatment for ICAD using bare metal stents reported hemodynamically significant ISR rates from 13.8–37% using bare metal coronary stents [15,16] and from 24.7–31% using self-expanding nitinol stents [22,23].

The efficacy of DESs in reducing neointimal hyperplasia, late luminal loss and angiographic restenosis over bare metal stents in the coronary vasculature has been extensively studied and demonstrated in randomized trials [24]. Reports on the application of DESs in the treatment of neurovascular stenoses are, however, sparse, with to our knowledge only 82 reported cases to date. The procedural and ISR results with coronary DES treatment in ICAD published so far are summarized in Table 2.

The results of this study with 3.8% recurrence and 0.9% stent occlusion rate at 78% DSA follow-up rate with more than 1 year average follow-up period are very promising. The very low periprocedural complication rate (0.9% procedure-related morbidity and mortality at and beyond 30 days) is also encouraging, especially in the mirror of the recently published result of the SAMMPRIS trial [27], where the poor results in the endovascular arm were mainly attributable to complications of the angioplasty and stenting procedure. It is a matter of debate whether these complications are due to device issues, limited experience and skills of the certified operators, poor patient selection, flaws of the trial concept or a combination thereof, which is most likely. Apart from the specific features of the device, proper patient selection is crucial in the endovascular treatment of intracranial stenoses. Patients with high-grade intracranial stenoses who have failed several attempts or regimens of medical treatment are frequently hemodynamically exhausted and therefore prone to postprocedural stroke and reperfusion hemorrhage. Given the low complication rate of intracranial angioplasty and stenting there should be more concern for treating patients too late than unnecessarily early.

Dissection of the cavernous ICA segment is unrelated to the flexibility of the balloon or stent. In some patients cavernous ICA stenoses are so calcified and therefore hard and the cavernous segment is in the same moment so fragile that there is a very thin line between dilatation and dissection of the vessel. These dissections occur with every method and are a part of the risk profile of these lesions and their treatment. The relative stiffness of coronary DESs is related to access issues but not necessarily to safety concerns.

The main drawback of the application of DESs in ICAD seems to be the high rate (7%) of failed attempts, which theoretically gets even worse considering the fact that patients in whom difficult supra-aortic anatomy or stenosis morphology were already known were not even attempted to be included in this cohort. The reason behind the high rate of procedural failure is the stiffness of the stent system of the early generations of coronary DESs such as the Coroflex® Please. Newer generation DESs are far more flexible, mainly as a result of the substantially reduced strut thickness. Coroflex® Please features 120 µ thick struts, whereas third generation DES systems, such as Element (Boston Scientific) or Xience (Abbott, Abbott Park, IL, USA) are made of 81 µ thick struts, substantially improving stent navigability (unpublished personal observation). The clinical practice was started when the Coroflex® Please was the latest stent. It is expected that newer generation DESs will combine the low recurrence rate with an improved maneuverability, making selected middle cerebral artery (MCA) and BA stenotic lesions also accessible.

Recently, the superiority of everolimus-eluting stents over paclitaxel-eluting stents with respect to lesion recurrence and clinical endpoints has been established in the cardiology literature with in-stent restenosis rates of 2.3% versus 5.7%, respectively [25,26]. The application of the newest generation, thin-strut DES systems (Element, Xience) with everolimus as the eluted drug for the treatment of ICAD may further improve the already encouraging recurrence rate.

The data presented here are limited in their scientific value in several aspects. There was no direct comparison with any other treatment method or device, e.g. medical treatment alone or bare metal stent (BMS) procedures. Data from primarily clinical series are certainly more prone to inconsistencies than those from a strictly regulated and externally monitored trial. Patient selection was based on the experience and discretion of the senior author, which introduces a certain level of individual or at least institutional decision-making. The data were collected in a single high volume center. Team experience and well-organized infrastructure are factors that contribute largely to the safety of a complex procedure such as intracranial angioplasty and stenting but are more or less independent from the specific device under evaluation. Therefore results achieved with a certain device or method may or may not be generally applicable to other operators and institutions.

In conclusion, the application of drug-eluting coronary stents for intracranial atherosclerotic disease is a safe and effective treatment option with low recurrence rates. Issues of lesion accessibility in difficult anatomical situations remain a problem, early experience with the application of the more flexible, newest generation thin-strut DES systems, however, shows promising results.

Conflict of Interest

The authors declare that there is no current or potential conflict of interest in relation to this article. Open Access was sponsored by B. Braun, Melsungen, Germany.

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

1.. Levy EI,Turk AS,Albuquerque FC,Niemann DB,Aagaard-Kienitz B,Pride L. Wingspan in-stent restenosis and thrombosis: incidence, clinical presentation, and managementNeurosurgery.Year: 2007616445010.1227/01.NEU.0000290914.24976.8317881980
2.. Chimowitz MI,Lynn MJ,Howlett-Smith H,Stern BJ,Hertzberg VS,Frankel MR. Warfarin-aspirin symptomatic intracranial disease trial investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosisN Engl J Med.Year: 200535213051610.1056/NEJMoa04303315800226
3.. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. The EC/IC Bypass Study Group. N Engl J Med. 1985;313:1191–1200.
4.. Sundt TM,Smith HC,Campbell JK,Vlietstra RE,Cucchiara RF,Stanson AW. Transluminal angioplasty for basilar artery stenosisMayo Clin Proc.Year: 198055673807442321
5.. Marks MP,Wojak JC,Al-Ali F,Jayaraman M,Marcellus ML,Connors JJ. Angioplasty for symptomatic intracranial stenosis: clinical outcomeStroke.Year: 20063710162010.1161/01.STR.0000206142.03677.c216497979
6.. Berg-Dammer E,Henkes H,Weber W,Berlit P,Kuhne D. Percutaneous transluminal angioplasty of intracranial artery stenosis: clinical results in 24 patientsNeurosurg Focus.Year: 19985e1310.3171/foc.1998.5.4.1617112212
7.. Vajda Z,Miloslavski E,Güthe T,Schmid E,Schul C,Albes G. Treatment of intracranial atherosclerotic arterial stenoses with a balloon-expandable cobalt chromium stent (Coroflex Blue): procedural safety, efficacy, and midterm patencyNeuroradiology.Year: 2010526455110.1007/s00234-009-0615-719921164
8.. Abou-Chebl A,Bashir Q,Yadav JS. Drug-eluting stents for the treatment of intracranial atherosclerosis: initial experience and midterm angiographic follow-upStroke.Year: 200536165810.1161/01.STR.0000190893.74268.fd
9.. Gupta R,Al-Ali F,Thomas AJ,Horowitz MB,Barrow T,Vora NA. Safety, feasibility, and short-term follow-up of drug-eluting stent placement in the intracranial and extracranial circulationStroke.Year: 2006372562610.1161/01.STR.0000242481.38262.7b16960090
10.. Qureshi AI,Kirmani JF,Hussein HM,Harris-Lane P,Divani AA,Suri MF. Early and intermediate-term outcomes with drug-eluting stents in high-risk patients with symptomatic intracranial stenosisNeurosurgery.Year: 20065910445110.1227/01.NEU.0000232862.06246.3D17143239
11.. Miao ZR,Feng L,Li S,Zhu F,Ji X,Jiao L. Treatment of symptomatic middle cerebral artery stenosis with balloon-mounted stents: long-term follow-up at a single centerNeurosurgery.Year: 200964798410.1227/01.NEU.0000335648.31874.3719050657
12.. Fields JD,Petersen BD,Lutsep HL,Nesbit GM,Liu KC,Dogan A. Drug eluting stents for symptomatic intracranial and vertebral artery stenosisInterv Neuroradiol.Year: 201117241721696666
13.. Mocco J,Darkhabani Z,Levy EI. Pharos neurovascular intracranial stent: elective use for a symptomatic stenosis refractory to medical therapyCatheter Cardiovasc Interv.Year: 200974642610.1002/ccd.2205419496116
14.. Henkes H,Miloslavski E,Lowens S,Reinartz J,Liebig T,Kühne D. Treatment of intracranial atherosclerotic stenoses with balloon dilatation and self-expanding stent deployment (WingSpan)Neuroradiology.Year: 200547222810.1007/s00234-005-1351-215912418
15.. Gröschel K,Schnaudigel S,Pilgram SM,Wasser K,Kastrup A. A systematic review on outcome after stenting for intracranial atherosclerosisStroke.Year: 200940340710.1161/STROKEAHA.108.532713
16.. Schumacher HC,Meyers PM,Higashida RT,Derdeyn CP,Lavine SD,Nesbit GM. Reporting standards for angioplasty and stent-assisted angioplasty for intracranial atherosclerosisStroke.Year: 2009403486510.1161/STROKEAHA.108.527580
17.. Güthe T,Miloslavski E,Vajda Z,Peters J,Bäzner H,Henkes H. Recurrent in-stent restenosis in a symptomatic nonatherosclerotic M1 plaque: successful treatment with paclitaxel-eluting balloon dilatation after repeated failure of conventional balloon reangioplastyClin Neuroradiol.Year: 201020165910.1007/s00062-010-0012-y20512301
18.. Vajda Z,Güthe T,Aguilar M,Heuschmid A,Schmid E,Bäzner E. Neurovascular in-stent stenoses: treatment with conventional and drug-eluting balloonsAJNR Am J Neuroradiol.Year: 2011321942710.3174/ajnr.A264421885715
19.. Higashida RT,Meyers PM. Intracranial angioplasty and stenting for cerebral atherosclerosis: new treatments for stroke are needed!NeuroradiologyYear: 2006483677210.1007/s00234-006-0071-616622698
20.. Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS). Accessed 17 July 2010.
22.. Turk AS,Levy EI,Albuquerque FC,Pride GL,Woo H,Welch BG. Influence of patient age and stenosis location on wingspan in-stent restenosisAJNR Am J Neuroradiol.Year: 20082923710.3174/ajnr.A086917989366
23.. Vajda Z, Schmid E, Güthe T, Klötzsch C, Lindner A, Niehaus L, et al. The modified Bose method for the endovascular treatment of intracranial atherosclerotic arterial stenoses using the Enterprise stent. Neurosurgery. 2012;70:91–101.
24.. Serruys PW,Kutryk MJ,Ong AT. Coronary-artery stentsN Engl J Med.Year: 20063544839510.1056/NEJMra05109116452560
25.. Stone GW,Rizvi A,Newman W,Mastali K,Wang JC,Caputo R. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery diseaseN Engl J Med.Year: 201036216637410.1056/NEJMoa091049620445180
26.. Stone GW,Midei M,Newman W,Sanz M,Hermiller JB,Williams J. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trialJAMA.Year: 200829919031310.1001/jama.299.16.190318430909
27.. Chimowitz MI,Lynn MJ,Derdeyn CP,Turan TN,Fiorella D,Lane BF. Stenting versus aggressive medical therapy for intracranial arterial stenosisN Engl J Med.Year: 2011365993100310.1056/NEJMoa110533521899409


[Figure ID: Fig1]
Fig. 1 

Preprocedural (a), postprocedural (b) and 3-year follow-up digital subtraction angiography (c) of a symptomatic, high-grade stenotic lesion of the left internal carotid artery in a 71-year-old female patient, treated by Coroflex® Please DES deployment.

[Figure ID: Fig2]
Fig. 2 

Development of a recurrent in-stent stenotic lesion in a 71-year-old male patient with a symptomatic, high-grade stenosis of the petrous segment of the right internal carotid artery. The postprocedural digital subtraction angiography image shows an excellent result after the deployment of a Coroflex® Please DES (b), the 7-month follow-up examination, however, revealed an asymptomatic, high-grade in-stent recurrent lesion as a result of intimal hyperplasia (c). Percutaneous transluminal angioplasty of the recurrent lesion was performed using a drug-eluting (paclitaxel) balloon (Sequent Please, B. Braun;d) with very good long-term result (e)

[TableWrap ID: Tab1] Table 1 

Lesion distribution and characteristics

Lesion location Severity of stenosis
50–70%/> 70%
Asymptomatic/symptomatic/multivessel disease
n % n %
ICA petrous 29/15 66/34 8/23/13 18/52/30
ICA cavernous 36/7 84/16 5/26/12 12/60/28
ICA paraclinoid 4/0 100/0 1/2/1 25/50/25
VA/V4 8/3 73/27 0/10/1 0/91/9
BA 3/1 75/25 0/4/0 0/100/0
Total 80/26 75/25 14/65/27 13/61/26

BA basilar artery,ICA internal carotid artery,VA vertebral artery

[TableWrap ID: Tab2] Table 2 

Review of previous studies on intracranial stenting with drug-eluting stents

Author No. of lesions attempted to treat Treated intradural/extradural lesions (%) Stenosis degree (%) Stent type Failed attempts (%) Adverse events (%) Procedure related morbidity/mortality at 30 days (%) Lesions with DSA follow-up (%) Average DSA follow-up time (months) Recurrence on DSA (%) Stent occlusion (%)
Pretreatment Posttreatment
Abou-Chebl et al. [8] 8 62/38 84 2 Cypher, Taxus 0 25 0 63 11 0 0
Gupta et al. [9] 29 n/a n/a n/a Cypher, Taxus 10 12 3 76 n/a 5 5
Qureshi et al. [10] 21 72/28 68 14 Cypher, Taxus 14 22 5 38 6 14 5
Miao et al. [11] 11 100/0 n/a n/a Cypher, Firebird n/a n/a n/a n/a n/a 9 0
Fields et al. [12] 13 n/a 80 2 Cypher, Taxus 0 0 18 73 8 38 0
This study 106 18/82 65 16 Coroflex® Please 4.7 3.8 0.9 78 12.5 3.9 0.9

DSA digital subtraction angiography,n/a not available

Article Categories:
  • Original Article

Keywords: Keywords Atherosclerosis, Intracranial stenosis, Drug-eluting stent, Endovascular, Stroke, Transitory ischemic attack.

Previous Document:  Ultrafast hydrogen sensing through hybrids of semiconducting single-walled carbon nanotubes and tin ...
Next Document:  One-year monitoring of core biomarker and digestive enzyme responses in transplanted zebra mussels (...